Skip to main content

Table 1 Patients’ characteristics at baseline

From: Systemic inflammation-based scores and mortality for all causes in HIV-infected patients: a MASTER cohort study

Variables Categories Total
n (%)
Total   8230
Gender Male 6013 (73.1)
Age at baseline (years) 18–24 610 (7.4)
25–34 2681 (32.6)
35–44 3054 (37.1)
45–54 1337 (16.3)
≥55 548 (6.7)
Mean (SD) 38.4 (10.1)
Country of origin Italy 6539 (80.7)
Others 1561 (19.3)
Year of enrolment 2000–2002 2077 (25.2)
2003–2006 2544 (30.9)
2007–2009 1943 (23.6)
2010–2012 1666 (20.2)
IDU Yes 4516 (35.8)
HBV/HCV co-infection Yes 2430 (29.5)
CD4 cell count 0–49 523 (6.8)
50–99 516 (6.7)
100–199 1007 (13.0)
200–349 1733 (22.4)
350–499 1659 (21.5)
≥500 2296 (29.7)
  Mean (SD) 395.5 (277.6)
CD4/CD8 ratio <0.3 2733 (40.3)
0.3–0.45 1356 (20.0)
≥0.45 2689 (39.7)
Mean (SD) 0.4 (0.3)
HIV-RNA log10 Mean (SD) 4.6 (1.0)
Late presentation Yes 4516 (58.6)
Advanced late presentation Yes 3135 (40.7)
Lymphocytes Mean (SD) 1962.4 (896.5)
Platelets Mean (SD) 220351.6 (80150.0)
Neutrophils Mean (SD) 2910.9 (1456.2)
PLR <100 2675 (39.1)
100–200 3132 (45.7)
≥200 1043 (15.2)
Mean (SD) 139.1 (100.8)
NLR <2 3826 (71.8)
2.4 1200 (22.5)
≥4 305 (5.7)
Mean (SD) 1.8 (1.5)
  1. Late presentation refers to persons diagnosed with HIV with a CD4 cell count below 350/mm3 or with an AIDS defining event regardless of the CD4 cell count in the 6 months following HIV diagnosis. Late presentation with HIV advanced disease refers to persons diagnosed with HIV with a CD4 cell count below 200/mm3 or with an AIDS defining event, regardless of CD4 cell count in the 6 months following HIV
  2. Abbreviations: SD standard deviation, IDU intravenous drug use, HBV Hepatitis B viruses, HCV Hepatitis C viruses, PLR platelet to lymphocyte ratio, NLR neutrophil to lymphocyte ratio